Massachusetts is moving Bill H.5303 to close a major coverage gap for perimenopause and menopause care, but a critical problem remains. While the legislation effectively removes insurance formulary loopholes for hormone replacement therapy (HRT), it leaves a 24-year-old blind spot completely intact: the state still requires absolutely no data collection or recurring audits to track whether these mandates are actually being honored in practice.

Massachusetts is moving H5303, An Act Expanding Access to Perimenopause and Menopause Care, through the Joint Committee on Health Care Financing. The bill requires hormone replacement therapy coverage across the state employee plan, MassHealth, and four private insurance chapters, with a parity clause barring insurers from applying prior authorization or step therapy to HRT more restrictively than to any other clinically appropriate hormonal drug.

The headline version of this story is access: Massachusetts is closing a coverage gap. However, the pathway that closes it has existed since 2002. The open question isn’t whether that pathway was real. It’s what data is required to validate whether the pathway activates or not.

The History of HRT Insurance Coverage in Massachusetts

Four sections of Massachusetts General Law — Chapter 175 §47W, Chapter 176A §8W, Chapter 176B §4W, and Chapter 176G §4O — were inserted into the General Laws by the same 2002 act, covering commercial insurance, Blue Cross-type hospital service plans, Blue Shield-type medical service plans, and HMOs respectively. Each establishes the same pathway: hormone replacement therapy for peri- and post-menopausal women must be covered “under the same terms and conditions” as other outpatient services and other prescription drugs.

The activation condition for that pathway sits one clause later, in every one of the four sections, worded identically: coverage is required, “provided that in covering all FDA approved prescription contraceptive methods, nothing in this section precludes the use of closed or restricted formulary.” Whether a given woman’s HRT prescription is actually accessible depends on a formulary decision made inside the insurer’s own systems. Nothing in the statute requires that decision to be disclosed, published, or reported to anyone. The pathway exists. Whether it activates for any individual patient is invisible by design — not because the statute hides it, but because the statute never asked the question.

Insurance Denials: Where HRT Data Collection Falls Short

In 2017, Massachusetts amended this same statutory family again, adding seven subsections to each of the four sections. For contraceptive coverage, the amendment built something with real measurement value: an expedited grievance process under Chapter 176O, which creates an actual denial record every time it’s used. A no-cost-sharing requirement, which is auditable against a claim. Limits on medical management techniques, which can be checked against a plan’s actual utilization rules.

None of that data infrastructure touches the HRT clause sitting one subsection above. A denied contraceptive claim generates a grievance record. A denied or formulary-restricted HRT claim, under the same statutory family, generates nothing the law requires anyone to capture. The same legislature, in the same act, built a way to measure access for one population and built nothing measurable for the other — not a smaller right, a smaller dataset.

Federal Data Highlights the Massachusetts HRT Blind Spot

For more than two decades, HRT carried an FDA boxed warning citing cardiovascular disease, breast cancer, and probable dementia risk. Contraceptives carried no comparable warning. That historical difference may be part of why the two drug classes ended up with different consumer-protection architecture in 2017. But it doesn’t change the more basic fact: no Massachusetts statute, in 2002 or 2017, ever required an insurer or a state agency to report how many women used this pathway, or how often formularies restricted access to it. For twenty-four years, that data simply did not exist anywhere in Massachusetts law.

On February 12, 2026, the FDA approved labeling changes removing those warnings from six menopausal hormone therapy products, the first batch in a review covering submissions from 29 companies. The same release contained the only number that has ever existed on this question at any meaningful scale: in 2020, an estimated 41 million U.S. women were ages 45 to 64, and only about 2 million women ages 46 to 65 received a hormone-therapy prescription that year.

That number came from a federal drug-safety review undertaken for an entirely different purpose. It did not come from the pathway Massachusetts built in 2002, or strengthened in 2017, to deliver this exact care. Twenty-four years into a coverage requirement, the first dataset to describe how many people it actually reached arrived from somewhere else.

Analyzing H5303: Expanded HRT Access Without Data Mandates

H5303 closes the formulary loophole. It inserts new, absolute coverage sections into the same four chapters — Section 231 into Chapter 175, parallel sections into 176A, 176B, and 176G — each banning the utilization controls the 2002 law explicitly permitted. The old sections remain unrepealed, sitting beside the new ones in the same statutory family.

What H5303 does not add is a reporting requirement. Nowhere in Sections 14 through 17 is an insurer required to disclose utilization rates, denial rates, or formulary compliance specific to HRT. The bill’s only data-collection mechanism is the special legislative commission created in Section 1 — a one-time study, due December 31, 2027, covering awareness, training gaps, and broad health disparities. It is not a recurring audit of whether the new mandate is being honored in practice.

The formulary loophole closes. The blind spot about whether it stays closed does not.

The Lozen Advisory Assessment: Unmeasured HRT Populations

Run this through the same four questions every entry in the Lozen Advisory tracker is built around. The pathway: an insurance coverage requirement, in continuous effect since 2002, strengthened in 2026. The activation condition: a formulary decision made inside the insurer’s own systems, never disclosed, never required to be disclosed, in either the original law or its replacement.

The data: a grievance-based record exists for a neighboring population — contraceptive users — since 2017; no equivalent record has ever existed for HRT, and H5303 does not create one. The unmeasured population: every woman whose formulary restricted her access, or whose claim was managed more strictly than a comparable hormonal drug, across twenty-four years with no record in Massachusetts law — until a federal agency, working on an unrelated drug-safety question, produced the first number anyone has ever had.

Massachusetts may be expanding access to menopause care. But access without measurement leaves the same question unanswered: not whether coverage exists, but whether anyone is required to count when women use it, are denied access, or are routed around it.

The Lozen Advisory Menopause Legislation Tracker audits federal and state menopause legislation by the pathway each bill establishes, the action required before that pathway activates, the data it can collect, and the populations left unmeasured.

lozenadvisory.com/menopause-legislation-tracker